Biopsy — The Definitive Procedure for Cancer Diagnosis

A biopsy involves obtaining a representative specimen of abnormal tissue to establish an accurate histopathological diagnosis. Pathologists examine the architecture of the tissue, evaluate cellular characteristics, and identify whether malignancy is present, as well as its specific histological subtype, degree of differentiation, and tumour grade.

Biopsies can be performed using various procedural modalities depending on the anatomical depth and location of the lesion. These range from needle biopsies (fine-needle aspiration or core needle biopsy) to incisional, excisional, endoscopic, or surgical approaches. Image guidance, using ultrasound, CT scanning, or fluoroscopy, is frequently employed to ensure precise targeting of deep-seated masses.

An accurate biopsy is essential before initiating any definitive cancer therapy. It prevents misdiagnosis and avoids unnecessary or inappropriate treatments. Beyond confirming whether a lesion is malignant, the biopsy sample provides tissue for grading, staging, and advanced biomarker testing. This information ensures that medical, surgical, and radiation oncologists can assemble the most effective, personalised treatment protocol for the patient.

Once obtained, the tissue undergoes histological processing, staining (such as haematoxylin and eosin), and microscopic evaluation. In modern pathology, biopsy samples are further evaluated using immunohistochemistry, in situ hybridisation, and molecular sequencing to detect therapeutic biomarkers, targetable mutations, and prognostic genetic markers.

Biopsies are conducted across almost all suspected solid tumours and haematological disorders, including breast, lung, prostate, colon, skin, liver, and thyroid cancers. They are also standard for diagnosing haematological malignancies, where bone marrow biopsies assess leukaemias, multiple myeloma, and systemic lymphomas.

Biopsy results dictate the entire clinical pathway. If benign, treatment may be limited to observation. If malignant, the specific histological subtype and margin status indicate whether initial management requires upfront surgical resection, neoadjuvant systemic therapy to shrink tumours, or primary definitive chemoradiotherapy. Biopsy findings also indicate whether lymph node dissection or further staging procedures are warranted.